157 related articles for article (PubMed ID: 21902542)
1. Adjuvant hormonal therapy use among women with ductal carcinoma in situ.
Livaudais JC; Hwang ES; Karliner L; Nápoles A; Stewart S; Bloom J; Kaplan CP
J Womens Health (Larchmt); 2012 Jan; 21(1):35-42. PubMed ID: 21902542
[TBL] [Abstract][Full Text] [Related]
2. Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women's health initiative.
Livaudais JC; Lacroix A; Chlebowski RT; Li CI; Habel LA; Simon MS; Thompson B; Erwin DO; Hubbell FA; Coronado GD
Cancer Epidemiol Biomarkers Prev; 2013 Mar; 22(3):365-73. PubMed ID: 23275187
[TBL] [Abstract][Full Text] [Related]
3. Ductal carcinoma in situ (DCIS): posttreatment follow-up care among Latina and non-Latina White women.
López ME; Kaplan CP; Nápoles AM; Livaudais JC; Hwang ES; Stewart SL; Bloom J; Karliner L
J Cancer Surviv; 2013 Jun; 7(2):219-26. PubMed ID: 23408106
[TBL] [Abstract][Full Text] [Related]
4. Selection of treatment among Latina and non-Latina white women with ductal carcinoma in situ.
Kaplan CP; Nápoles AM; Hwang ES; Bloom J; Stewart S; Nickleach D; Karliner L
J Womens Health (Larchmt); 2011 Feb; 20(2):215-23. PubMed ID: 21128819
[TBL] [Abstract][Full Text] [Related]
5. Satisfaction with treatment decision-making and treatment regret among Latinas and non-Latina whites with DCIS.
López ME; Kaplan CP; Nápoles AM; Hwang ES; Livaudais JC; Karliner LS
Patient Educ Couns; 2014 Jan; 94(1):83-9. PubMed ID: 24207116
[TBL] [Abstract][Full Text] [Related]
6. Patterns of care analysis among women with ductal carcinoma in situ in North Carolina.
Jackson LC; Camacho F; Levine EA; Anderson RT; Stewart JH
Am J Surg; 2008 Feb; 195(2):164-9. PubMed ID: 18096124
[TBL] [Abstract][Full Text] [Related]
7. Trends in incidence and treatment for ductal carcinoma in situ in Hispanic, American Indian, and non-Hispanic white women in New Mexico, 1973-1994.
Adams-Cameron M; Gilliland FD; Hunt WC; Key CR
Cancer; 1999 Mar; 85(5):1084-90. PubMed ID: 10091792
[TBL] [Abstract][Full Text] [Related]
8. The effect of system-level access factors on receipt of reconstruction among Latina and white women with DCIS.
Kaplan CP; Karliner LS; Hwang ES; Bloom J; Stewart S; Nickleach D; Quinn J; Thrasher A; Nápoles AM
Breast Cancer Res Treat; 2011 Oct; 129(3):909-17. PubMed ID: 21533531
[TBL] [Abstract][Full Text] [Related]
9. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
Farias AJ; Du XL
J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
[TBL] [Abstract][Full Text] [Related]
10. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.
Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR
J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753
[TBL] [Abstract][Full Text] [Related]
11. Racial and ethnic differences in adjuvant hormonal therapy use.
Livaudais JC; Li C; John EM; Terry MB; Daly M; Buys SS; Habel L; Thompson B; Yanez ND; Coronado GD
J Womens Health (Larchmt); 2012 Sep; 21(9):950-8. PubMed ID: 22731764
[TBL] [Abstract][Full Text] [Related]
12. Ductal carcinoma in situ: knowledge of associated risks and prognosis among Latina and non-Latina white women.
Parikh AR; Kaplan CP; Burke NJ; Livaudais-Toman J; Hwang ES; Karliner LS
Breast Cancer Res Treat; 2013 Sep; 141(2):261-8. PubMed ID: 23996141
[TBL] [Abstract][Full Text] [Related]
13. Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ.
Zhao H; Hei N; Wu Y; Chan W; Lei X; Cameron C; Chang S; Chavez-MacGregor M; Giordano SH
Cancer; 2017 May; 123(6):940-947. PubMed ID: 27780311
[TBL] [Abstract][Full Text] [Related]
14. Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy.
Biggers A; Shi Y; Charlson J; Smith EC; Smallwood AJ; Nattinger AB; Laud PW; Neuner JM
J Clin Oncol; 2016 Dec; 34(36):4398-4404. PubMed ID: 27998232
[TBL] [Abstract][Full Text] [Related]
15. Racial and geographic disparities in adherence and discontinuation to adjuvant endocrine therapy in Texas Medicaid-insured patients with breast cancer.
Farias AJ; Wu WH; Du XL
Med Oncol; 2018 Jun; 35(7):113. PubMed ID: 29926275
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen Acceptance and Adherence among Patients with Ductal Carcinoma In Situ (DCIS) Treated in a Multidisciplinary Setting.
Karavites LC; Kane AK; Zaveri S; Xu Y; Helenowski I; Hansen N; Bethke KP; Rasmussen-Torvik LJ; Khan SA
Cancer Prev Res (Phila); 2017 Jul; 10(7):389-397. PubMed ID: 28559459
[TBL] [Abstract][Full Text] [Related]
17. Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer.
Livaudais JC; Hershman DL; Habel L; Kushi L; Gomez SL; Li CI; Neugut AI; Fehrenbacher L; Thompson B; Coronado GD
Breast Cancer Res Treat; 2012 Jan; 131(2):607-17. PubMed ID: 21922245
[TBL] [Abstract][Full Text] [Related]
18. Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study.
Nguyen TT; Hoskin TL; Day CN; Habermann EB; Goetz MP; Boughey JC
Ann Surg Oncol; 2017 Oct; 24(10):2989-2998. PubMed ID: 28766214
[TBL] [Abstract][Full Text] [Related]
19. Recent trends and racial/ethnic differences in the incidence and treatment of ductal carcinoma in situ of the breast in California women.
Innos K; Horn-Ross PL
Cancer; 2003 Feb; 97(4):1099-106. PubMed ID: 12569612
[TBL] [Abstract][Full Text] [Related]
20. A tracking and feedback registry to reduce racial disparities in breast cancer care.
Bickell NA; Shastri K; Fei K; Oluwole S; Godfrey H; Hiotis K; Srinivasan A; Guth AA
J Natl Cancer Inst; 2008 Dec; 100(23):1717-23. PubMed ID: 19033569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
